Drug intelligence / Profile preview

parabacteroides goldsteinii outer membrane vesicles

Development stage: Preclinical
Modality: Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral, Subcutaneous

Overview

Parabacteroides goldsteinii outer membrane vesicles (Pg-OMVs) are a preclinical biologic therapeutic derived from the gut commensal bacterium *Parabacteroides goldsteinii*. These nanoscale extracellular vesicles contain bioactive components and have demonstrated immunomodulatory activity. In preclinical models, Pg-OMVs administered orally or subcutaneously can travel to inflamed tissues and suppress inflammation. The mechanism of action involves the suppression of neutrophil extracellular trap (NET) formation through activation of the Cav-1-Nrf2 signaling axis, modulation of inflammatory cytokines (such as downregulating IL-23/Th17 signaling), and regulation of bile acid metabolism. [1, 4, 7, 10] It is being investigated for inflammatory conditions including rheumatoid arthritis, psoriasis, and acute lung injury. [4, 10] Currently, it is an experimental compound with no identified commercial developer.

Targets

PPARG (Peroxisome proliferator-activated receptor gamma)IL-12R (Interleukin-12 receptor)

Beyond the preview

Go deeper on parabacteroides goldsteinii outer membrane vesicles.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on parabacteroides goldsteinii outer membrane vesicles.

Explore the full profile